VKTX241004C56000
- 13.95
- 0.000.00%
Viking Therapeutics Newsroom
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
New Small-cap Buy and Sell Ideas for Oppenheimer's 50/50 List
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Is Viking Therapeutics Inc. (VKTX) the Best Performing Small-Cap Stock in 2024?
Oppenheimer points out the next "trend" in weight loss drugs: oral over-the-counter medications.
The competition to develop oral weight loss drugs is heating up.
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
Next Frontier in Anti-obesity Landscape: Oral GLP-1s With Potential OTC Switch
Viking Therapeutics Analyst Ratings
Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $138
Viking Therapeutics Unusual Options Activity For September 24
Weight loss candidate drug nimacimab safety approved. Skye (SKYE.US) stock price soared 11%.
Skye Bioscience's stock price soared 11%, benefiting from the safety differences between its weight loss candidate drug nimacimab and novo-nordisk a/s's monlunabant.
10 Health Care Stocks With Whale Alerts In Today's Session
Skye Stock Rallies 22% Following Weight-loss Drug Update
Viking Therapeutics, Inc. (VKTX): Biotech Breakthrough or Short Sellers' Target?
Viking Therapeutics(VKTX.US) Officer Sells US$15.31 Million in Common Stock
$Viking Therapeutics(VKTX.US)$ Officer Lian Brian sold 216.13K shares of common stock on Sep 20, 2024 at an average price of $70.8303 for a total value of $15.31 million.Source: Announcement What is
Viking Therapeutics CEO Sells Over $15m in Company Stock
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today